Peptide hormones, from classical ligands like insulin to engineered molecules like GLP-1 receptor agonists, represent a major class of therapeutics that have been transformed by peptide engineering. The peptide therapeutics market is projected to reach US$ 189.5 billion by 2032[reference:126], with peptide hormones contributing significantly to this growth.
Insulin was the first peptide hormone to be used therapeutically, and its development established the foundation for peptide drug development. Native insulin has a short half-life, requiring multiple daily injections. Engineered insulin analogs with modified pharmacokinetic properties have been developed, including rapid-acting analogs for mealtime coverage and long-acting analogs for basal coverage.
GLP-1 receptor agonists represent a more recent success in peptide hormone engineering. Native GLP-1 has a half-life of approximately 2 minutes due to rapid degradation by DPP-4. Engineered GLP-1 analogs resist degradation, with half-lives ranging from 13 hours (liraglutide) to 7 days (semaglutide). These extended half-lives enable once-daily or once-weekly dosing, dramatically improving patient convenience and adherence.
Engineering strategies for peptide hormones include amino acid substitution (to resist enzymatic degradation), fatty acid conjugation (to promote albumin binding and extend half-life), and PEGylation (to increase molecular size and reduce renal clearance). Each strategy has advantages and limitations, and the optimal approach depends on the specific hormone and therapeutic application.
Beyond insulin and GLP-1, engineered peptide hormones are being developed for other indications. Amylin analogs, PYY analogs, and oxyntomodulin analogs are in development for metabolic diseases. Peptide hormone engineering is also being applied to hormones involved in growth, reproduction, and bone metabolism.
At PeptideHub, we support peptide hormone engineering with custom synthesis of analogs and modified peptides. Our experienced team can guide the design and synthesis of engineered peptide hormones, supporting the development of next-generation therapeutics.